Nucleic Acid News and Research

RSS

New COVID-19 test speeds up access to urgent care

The first analysis of a new point-of-care "nucleic acid test" for SARS-CoV-2 in a UK hospital setting shows these machines dramatically reduce time spent on COVID-19 'holding' wards - allowing patients to be treated or discharged far quicker than with current lab testing set-ups.

3 Jun 2020

New detection platform for rapid diagnosis of infectious diseases

The prompt, precise, and massive detection of a virus is the key to combat infectious diseases such as Covid-19.

1 Jun 2020

Study reveals how essential SARS-CoV-2 protein can be stabilized and scaled for production

A research group from the University of Texas in Austin described a high-yield production of a stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-protein) that may accelerate the development of vaccines and diagnostic tests. This methodological 'tour de force' paper is currently available on the bioRxiv* preprint server.

1 Jun 2020

No specific COVID-19-linked lesions found despite extensive organ injury

A recent paper published online on the preprint server medRxiv in May 2020 reports autopsy results on COVID-19 patients. The paper concludes that there were no specific hallmark lesions of COVID-19 in any of the many organs found to be injured by the infection in patients who died of the disease.

1 Jun 2020

Scientists track SARS-CoV-2 in wastewater

Epidemiologist David Larsen, from Syracuse University and microbiologists Hyatt Green, from the College of Environmental Science and Forestry and Frank Middleton, from Upstate Medical University are lead members of a multi-institution research project that is expected to have global application in future efforts to track and contain Sudden Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus Disease 2019 (COVID-19).

30 May 2020

Toshiba and Shinshu University jointly develop a 'tumor-tropic liposome technology' for gene therapy

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a “tumor-tropic liposome technology” for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

30 May 2020

SARS-CoV-2 RNA in blood tests not associated with infectious virus

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has challenged hospitals and laboratory services worldwide. Diagnostic testing for SARS-CoV-2 initially lagged but is now primarily based on the use of reverse transcriptase-polymerase chain reaction (RT-PCR) to detect viral nucleic RNA in the samples. However, viral RNA has also been reported in several small series of cases, though its significance and frequency remain unclear.

27 May 2020

EKF secures COVID-19 novel sample collection kit manufacturing and supply contracts

EKF Diagnostics, the global in vitro diagnostics company, announces it has secured new contracts for the manufacture and supply of a novel, patented sample collection device which allows COVID-19 samples to be rapidly inactivated in the collection tube, avoiding contamination and preserving RNA without need for refrigeration.

From EKF Diagnostics 26 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020

Saliva testing allows quick, accurate and non-invasive SARS-CoV-2 detection

Saliva is one of the ways people can transmit the novel coronavirus to others, but it may also help combat coronavirus disease (COVID-19). Scientists are now looking into using saliva to test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19 disease.

20 May 2020

Experts urge further improvements in COVID-19 testing to increase speed and availability

In an important, comprehensive, and timely review, an expert team from the University of California Berkeley details the methodologies used in nucleic acid-based tests for detecting the presence of SARS-CoV-2, the virus that causes COVID-19.

20 May 2020

Methodologies to detect the presence of SARS-CoV-2

20 May 2020

Viral shedding seen in plasma donors who have recovered from COVID-19

Researchers from the University of Wisconsin-Madison have found that plasma donors who have recovered from the deadly COVID-19 infection were still shedding viral RNA. This could be significant they write in their article titled, “Prolonged viral RNA shedding after COVID-19 symptom resolution in older convalescent plasma donors,” that is published on the preprint server Medrxiv* prior to peer review.

15 May 2020

New textile coating prevents viruses from adhering to the surface

Masks, gowns, and other personal protective equipment (PPE) are essential for protecting healthcare workers. However, the textiles and materials used in such items can absorb and carry viruses and bacteria, inadvertently spreading the disease the wearer sought to contain.

14 May 2020

Varied performance of SARS-CoV-2 antibody tests in detecting protective immunity

The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.

11 May 2020

No evidence COVID-19 is spread by fecal-oral transmission

A new study published on the preprint server medRxiv* in May 2020 shows that in patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pharyngeal and fecal samples, the virus persists longer in the fecal samples than in the pharyngeal samples. However, fecal-oral transmission does not appear to occur.

10 May 2020

FDA grants emergency approval for first at-home saliva-based coronavirus test

Rutgers' RUCDR Infinite Biologics received an amended emergency use authorization from the FDA late Thursday for the first SARS-CoV-2 coronavirus test that will allow people to collect their own saliva at home and send to a lab for results.

8 May 2020

New breakthrough may help cure prion disease

A molecular biologist at the University of Massachusetts Amherst who has for decades studied the nightmarish group of fatal diseases caused by prions - chronic wasting disease in deer, mad cow in cattle and its human analog - credits a middle-of-the-night dream for a crucial insight, a breakthrough she hopes could lead to a cure.

6 May 2020

Rapid affordable viral testing kits for low-resource settings

A new paper published on the preprint server bioRxiv* in April 2020 reports a low-cost, sensitive and rapid RT-PCR testing kit for the detection of COVID-19. If validated, this could provide an enormous boost to diagnostic testing in low-resource regions of the world.

4 May 2020

Using Multiplex Assays to Discover Biomarkers for Parkinson’s Disease

In this interview, Dr. Polinski and Dr. Atabakhsh discuss the importance of developing biomarkers for Parkinson’s and the partnership between MJFF and Abcam.

From Abcam 1 May 2020